{"id":172695,"date":"2025-06-10T10:26:10","date_gmt":"2025-06-10T10:26:10","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/172695\/"},"modified":"2025-06-10T10:26:10","modified_gmt":"2025-06-10T10:26:10","slug":"jupiter-neurosciences-launches-resveratrol-powered-supplements","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/172695\/","title":{"rendered":"Jupiter Neurosciences launches resveratrol-powered supplements"},"content":{"rendered":"

New consumer longevity brand to support company\u2019s clinical development of therapeutics based on proprietary resveratrol delivery platform.<\/strong> <\/p>\n

Clinical stage biotech Jupiter Neurosciences<\/a> has officially launched a new line of consumer supplements designed to support health and performance, broadening its focus from clinical-stage pharmaceuticals into the consumer longevity market. The company is leveraging its proprietary micellar resveratrol delivery technology to the nutraceutical space, offering a range of supplements designed to enhance healthspan, cognitive clarity and metabolic resilience.<\/p>\n

The new supplement brand, called Nugevia, emerges from Jupiter\u2019s primary focus on optimizing the therapeutic delivery of resveratrol to target neuroinflammation and combat neurodegenerative diseases. Resveratrol, a compound long recognized<\/a> for its potential antiaging and anti-inflammatory effects, has been limited in its clinical utility due to poor bioavailability and adverse gastrointestinal effects at higher doses. Jupiter claims its proprietary platform, JOTROL, addresses these limitations through a micellar formulation that improves absorption while maintaining a strong safety profile. In clinical studies, the company says JOTROL demonstrated a ninefold increase in bioavailability without the gastrointestinal side effects typically associated with high-dose resveratrol.<\/p>\n

\u201cThe launch of Nugevia is the natural next step in translating our science into broad, real-world impact,\u201d said Jupiter CEO Christer Ros\u00e9n. \u201cBy building on the same proprietary technology platform that underpins our prescription drug development, we\u2019re delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.\u201d<\/p>\n

The first three formulations \u2013 focused on mitochondrial function, cognitive enhancement and internal wellness \u2013 are set to launch through a direct-to-consumer model in the third quarter of 2025. The supplements incorporate JOTROL as a core ingredient and blend resveratrol with other synergistic compounds, using an \u201cintelligent stacking\u201d strategy intended to promote cellular health, optimize delivery across the blood-brain barrier and support holistic performance.<\/p>\n

After raising $11 million in its IPO last December<\/a>, the commercial expansion also creates a financial engine to support Jupiter\u2019s ongoing clinical development efforts. The company\u2019s lead pharmaceutical program, focused on the treatment of central nervous system disorders, is progressing toward a Phase 2a clinical trial in Parkinson\u2019s following positive Phase 1 safety results.<\/p>\n

\u201cNugevia represents more than a product launch \u2013 it\u2019s a strategic engine for growth,\u201d said Ros\u00e9n. \u201cBy leveraging our core science in a consumer format, we\u2019re creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It\u2019s smart capital allocation with real scientific impact.\u201d<\/p>\n

Photographs courtesy of Jupiter Neurosciences.<\/strong> <\/p>\n","protected":false},"excerpt":{"rendered":"New consumer longevity brand to support company\u2019s clinical development of therapeutics based on proprietary resveratrol delivery platform. Clinical…\n","protected":false},"author":2,"featured_media":172696,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4318],"tags":[105,71744,4716,35721,2669,12,4434,71745,4471,16,15],"class_list":{"0":"post-172695","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-nutrition","8":"tag-health","9":"tag-jupiter-neurosciences","10":"tag-longevity","11":"tag-neurodegeneration","12":"tag-neuroinflammation","13":"tag-news","14":"tag-nutrition","15":"tag-resveratrol","16":"tag-supplements","17":"tag-uk","18":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114658593167718034","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/172695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=172695"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/172695\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/172696"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=172695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=172695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=172695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}